RAYALDEE caps moll 30 mcg bte 30 pce

7680676140014 CH-67614 H05BX05 07.02.3.

Reimbursement limitations:

RAYALDEE

Pour le traitement de l'hyperparathyroïdie secondaire (SHPT) avec des taux plasmatiques d'iPTH entre ≥85 et …

RAYALDEE caps moll 30 mcg bte 30 pce
RAYALDEE caps moll 30 mcg bte 30 pce
RAYALDEE caps moll 30 mcg bte 30 pce
1 / 3
google

Details

Product number
6761401
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
calcifediolum 30 µg ut calcifediolum monohydricum, paraffinum solidum, paraffinum liquidum, hypromellosum, glyceroli monostearas 40-55, macrogolglyceridorum laurates, ethanolum anhydricum 3.944 mg, E 321, Kapselhülle: amylum hydroxypropylum, carrageenanum, sorbitolum liquidum partim deshydricum corresp. sorbitolum 18 mg, dinatrii phosphas corresp. natrium 0.3 mg, titanii dioxidum, E 133, aqua purificata pro capsula.

Articles (1)

Rayaldee 30 µg, Weichkapseln retardiert
Weichkapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
22/03/2022
Patient information leaflet
Français
22/03/2022
Patient information leaflet
Italien
22/03/2022
Professional SmPC
Allemand
22/03/2022
Professional SmPC
Français
22/03/2022
Professional SmPC
Italien
22/03/2022

Detailed composition

Substance Quantity Type Category
(N/A)
30.0 UG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
3.944 MG Substance HBESI
(N/A)
- Substance ANTOX
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
18.0 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
0.3 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance FIMDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 112.30
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/03/2022

Authorization holder

Vifor Fresenius Medical Care

9014 St. Gallen

Authorization information

Swissmedic authorization number
67614
Drug name
Rayaldee, Weichkapseln retardiert
Galenic form
KAPS
ATC Code
H05BX05
Authorization status
Z
Dispensation category
B
First authorization
22/12/2020
Authorization expiration date
31/12/9999
IT number
07.02.3.
Domain
Human medicine
Field of application
Rayaldee ist zur Behandlung von sekundärem Hyperparathyreoidismus (SHPT) bei Erwachsenen mit chronischer Niereninsuffizienz (CKD) im Stadium 3 oder 4 und 25- Hydroxyvitamin-D-Serumwerten <30 ng/ml indiziert.

Packaging details

Description (FR)
RAYALDEE caps moll 30 mcg bte 30 pce
Description (DE)
RAYALDEE Weichkaps 30 mcg Ds 30 Stk
Market launch
22/12/2020
Narcotic (BTM)
No